Juli 18, 2016

Key points:

• Full-year sales expected to be approximately $37M (11% growth) – within guidelines.
• Likely EBITDA ($4.5M-$5.5M) and NPAT ($2.8M- $3.2M) also within guidelines.
• Final numbers subject to audit. Full-year results expected to be announced in late August.
• Compumedics expects similar revenue growth in FY17, with potential to grow revenue base faster based on breakout potential of eHealth initiatives (Somfit & Nexus 360) and MEG. Profits will increase accordingly.
• Results achieved during a period of record investment, strongly reinforcing the company’s new high-growth, step-out initiatives: eHealth (Nexus 360 and Somfit) and MEG neuroimaging.

Compumedics Limited [ASX: CMP] – a leader in medical devices for sleep, brain and ultrasonic blood-flow monitoring – today announced that preliminary results show the company will generate increased revenue and profits in line with guidance for the full year ending 30 June 2016.

Full-year sales are expected to be $37 million (11% growth) while EBITDA is expected to be between $4.5–5.5 million and NPAT $2.8-3.2million.

Final full-year results will be subject to audit, and will be released to the Australian Stock Exchange around August 25, 2016.

The indicative results reflect several positive outcomes from the company’s continuing process of renewing growth in key world markets, as well as relocating key manufacturing activities to lower-cost economies.

Specifically, the company has achieved the following milestones in the past twelve months:

• A 14% increase in total orders taken for FY16 at $38.4m compared to $33.8m
• Continued outsourcing of manufacturing, with most main product lines transferred
• New low-cost Grael product line has commenced shipping
• Strategic discussions in relation to Somfit
• Strong commercial progress with key step out technologies including MEG brain imaging and digital health (Somfit consumer sleep project and clinical cloud)

More detailed analysis will be provided in the full-year results.

The company will conduct an investment roadshow in Melbourne and Sydney following the full-year results.

Currently, the proposed dates will be:

Melbourne – 29 and 30 August;
Sydney – 31 August and 1 September.


About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.

Executive Chairman Dr David Burton founded Compumedics in 1987. In the same year the company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.

For further information please contact:

Dr David Burton
Executive Chairman, CEO Executive Director
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

David Lawson
Chief Financial Officer
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Investor relations & media enquires:

Rod North
Managing Director
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: 0408 670 706

Richard Allen
Oxygen Financial PR
Ph: + 61 3 9915 6341
Mob: 0403 493 049